CN101512000B - 生产寡肽的方法 - Google Patents
生产寡肽的方法 Download PDFInfo
- Publication number
- CN101512000B CN101512000B CN200780024534.6A CN200780024534A CN101512000B CN 101512000 B CN101512000 B CN 101512000B CN 200780024534 A CN200780024534 A CN 200780024534A CN 101512000 B CN101512000 B CN 101512000B
- Authority
- CN
- China
- Prior art keywords
- oligopeptide
- fusion protein
- restriction enzyme
- site
- protease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (24)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0608368.7 | 2006-04-28 | ||
GBGB0608368.7A GB0608368D0 (en) | 2006-04-28 | 2006-04-28 | Process for making Oligopeptides |
PCT/GB2007/050225 WO2007125371A2 (en) | 2006-04-28 | 2007-04-30 | Process for making oligopeptides |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101512000A CN101512000A (zh) | 2009-08-19 |
CN101512000B true CN101512000B (zh) | 2016-08-03 |
Family
ID=36589936
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200780024534.6A Active CN101512000B (zh) | 2006-04-28 | 2007-04-30 | 生产寡肽的方法 |
Country Status (7)
Country | Link |
---|---|
US (1) | US9382546B2 (zh) |
EP (1) | EP2041286B1 (zh) |
CN (1) | CN101512000B (zh) |
AT (1) | ATE493497T1 (zh) |
DE (1) | DE602007011616D1 (zh) |
GB (1) | GB0608368D0 (zh) |
WO (1) | WO2007125371A2 (zh) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0713978A2 (pt) | 2006-06-28 | 2012-11-27 | Statens Seruminstitut | expansão do repertório de células t para incluir epìtopos subdominantes através da vacinação com antìgeneos leberados como fragmentos de protéinas ou coquetéis de peptìdeo |
EP2620446A1 (en) | 2012-01-27 | 2013-07-31 | Laboratorios Del Dr. Esteve, S.A. | Immunogens for HIV vaccination |
CN105753989A (zh) * | 2014-12-15 | 2016-07-13 | 牛津疫苗医学生物科技(英国)有限公司 | 人工多抗原融合蛋白及其制备和应用 |
AU2020384323A1 (en) | 2019-11-14 | 2022-06-02 | Aelix Therapeutics, S.L. | Dosage regimens for vaccines |
GB202017118D0 (en) | 2020-10-28 | 2020-12-09 | Oxford Vacmedix Uk Ltd | Coronavirus polypeptide |
GB202017119D0 (en) | 2020-10-28 | 2020-12-09 | Oxford Vacmedix Uk Ltd | Polypeptides for cancer treatment |
GB202019767D0 (en) | 2020-12-15 | 2021-01-27 | Chain Biotechnology Ltd | Compostitions and methods |
WO2022238689A1 (en) | 2021-05-11 | 2022-11-17 | Oxford Vacmedix UK Limited | Vaccine formulation comprising recombinant overlapping peptides and native prtoeins |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1193998A (zh) * | 1995-04-11 | 1998-09-23 | 麦克公司 | 以二肽基础的化合物生产的生物方法 |
WO2004002415A2 (en) * | 2002-06-27 | 2004-01-08 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for modulating a cytotoxic t lymphocyte immune response |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5795974A (en) * | 1993-12-10 | 1998-08-18 | University Of Utah Research Foundation | Mycoplasma arthritidis superantigen |
SE9903031D0 (sv) * | 1999-08-27 | 1999-08-27 | Eurodiagnostica Ab | Peptide mixture and vaccine against a chronic viral infection |
CN1255548C (zh) * | 2001-06-15 | 2006-05-10 | 霍夫曼-拉罗奇有限公司 | gp41片段的乙酰化 |
-
2006
- 2006-04-28 GB GBGB0608368.7A patent/GB0608368D0/en not_active Ceased
-
2007
- 2007-04-30 DE DE602007011616T patent/DE602007011616D1/de active Active
- 2007-04-30 EP EP07733646A patent/EP2041286B1/en active Active
- 2007-04-30 CN CN200780024534.6A patent/CN101512000B/zh active Active
- 2007-04-30 AT AT07733646T patent/ATE493497T1/de not_active IP Right Cessation
- 2007-04-30 US US12/298,835 patent/US9382546B2/en active Active
- 2007-04-30 WO PCT/GB2007/050225 patent/WO2007125371A2/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1193998A (zh) * | 1995-04-11 | 1998-09-23 | 麦克公司 | 以二肽基础的化合物生产的生物方法 |
WO2004002415A2 (en) * | 2002-06-27 | 2004-01-08 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for modulating a cytotoxic t lymphocyte immune response |
Non-Patent Citations (2)
Title |
---|
Rika Draenert等.Comparison of overlapping peptide sets for detection of antiviral CD8 and CD4 T cell responses.《Journal of Immunological Methods》.2003,第275卷19-29. * |
Velpandi Ayyavoo等.Immunogenicity of a novel DNA vaccine cassette expressing multiple human immunodeficiency virus (HIV-1) accessory genes.《AIDS》.2000,第14卷1-9. * |
Also Published As
Publication number | Publication date |
---|---|
EP2041286B1 (en) | 2010-12-29 |
WO2007125371A2 (en) | 2007-11-08 |
US20100291061A1 (en) | 2010-11-18 |
CN101512000A (zh) | 2009-08-19 |
US9382546B2 (en) | 2016-07-05 |
WO2007125371A3 (en) | 2008-03-13 |
GB0608368D0 (en) | 2006-06-07 |
EP2041286A2 (en) | 2009-04-01 |
DE602007011616D1 (de) | 2011-02-10 |
ATE493497T1 (de) | 2011-01-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101512000B (zh) | 生产寡肽的方法 | |
KR101548143B1 (ko) | 극대화된 Gag 및 Nef를 수지상 세포에 표적화시킴을 기본으로 하는 HIV 백신 | |
EP2928491B1 (en) | Fusion proteins for use as immunogenic enhancers for inducing antigen-specific t cell responses | |
EP0714444B1 (en) | Dampening of an immunodominant epitope of an antigen for use in plant, animal and human vaccines and immunotherapies | |
ES2341429T3 (es) | Mejoras en las respuestas inmunitarias al vih o relacionadas con las mismas. | |
CN102836441B (zh) | 于感染性与恶性疾病的治疗中提升免疫反应的方法 | |
KR101686942B1 (ko) | 뎅기 바이러스 다중 서브타입에 대항하는 신규한 백신 | |
CN111358953A (zh) | 一种高效诱导机体体液免疫应答的疫苗载体、其制备方法及用途 | |
CA3015530A1 (en) | Virus vectors expressing multiple epitopes of tumor associated antigens for inducing antitumor immunity | |
JP2008541768A5 (zh) | ||
JPH09503902A (ja) | 組み換えウイルス免疫治療 | |
JP2001512308A (ja) | 合成hiv gag遺伝子 | |
EP3294329A1 (en) | Novel baculovirus vectors and methods of use | |
CA2985381A1 (en) | Vaccine compositions against porcine reproductive and respiratory syndrome and porcine circovirus associated diseases | |
JP2012097111A (ja) | 葉酸結合タンパク質の改変体による腫瘍免疫の誘導 | |
KR20230084478A (ko) | 면역원성 코로나 바이러스 융합 단백질 및 관련 방법 | |
EP2374811A1 (en) | IgG Fc/HIV-gp120/c3d fusion protein | |
TW200932908A (en) | Antigenic compositions and use of same in the targeted delivery of nucleic acids | |
CN104829732A (zh) | 一种重组蛋白及其在昆虫杆状病毒表达系统中的表达方法 | |
CN101081871A (zh) | 蛋白转导域4-凋亡素融合蛋白(PTD4-Apoptin)及其制法和应用 | |
Acha-Orbea et al. | Immune response to MMTV infection | |
WO2022087031A1 (en) | Compositions comprising hiv envelopes to induce hiv-1 antibodies | |
EP3275462A1 (en) | Virus-like particles with high-density coating for the production of neutralizing antibodies | |
Pistello et al. | AIDS vaccination studies with an ex vivo feline immunodeficiency virus model: analysis of the accessory ORF-A protein and DNA as protective immunogens | |
WO2021081437A2 (en) | Compositions comprising v2 opt hiv envelopes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: DANA-FARBER CANCER INSTITUTE, INC. Effective date: 20130314 |
|
C41 | Transfer of patent application or patent right or utility model | ||
C53 | Correction of patent of invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Jiang Shisong Inventor after: R.Ruprecht Inventor before: Jiang Shisong |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: JIANG SHISONG TO: JIANG SHISONG R. RUPRECHT |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20130314 Address after: Oxford, UK Applicant after: Isis Innovation Ltd. Applicant after: Dana Farber Cancer Institute Address before: Oxford, UK Applicant before: Isis Innovation Ltd. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee | ||
CP03 | Change of name, title or address |
Address after: Oxfordshire, UK Patentee after: University of Oxford science and Technology Innovation Co., Ltd. Patentee after: Dana Farber Cancer Institute Address before: Oxford, UK Patentee before: Isis Innovation Ltd. Patentee before: Dana Farber Cancer Institute |